Related to Aileron to Leverage Scripps’ Click Chemistry to Develop Peptide and Protein Therapeutics

• BARDA to Give Neumedicines $17M to Progress Radiation Countermeasure
  
• RXi Restructures to Focus on Cancer and Spins Out RNAi Therapeutics
  
• Children’s Oncology Group Joins Forces with Apeiron in Pediatric Neuroblastoma Trial
  
• Sangamo Stock Nosedives on Decision to Discontinue Lead ZFP Candidate
  
• Unigene and Nordic Set Up Joint Venture to Develop Three Peptide Therapeutics
  
• MJFF Awards AFFiRiS $1.5M for Phase I Study with Peptide-Based Parkinson Disease Vaccine
  
• Rationally Designed Mini-Peptides Could Offer New Therapeutic Approach to Iron Overload
  
• BARDA Rejects Maxygen’s Proposal to Develop MAXY-G34 for Acute Radiation Syndrome
  
• Digna Biotech Takes Back Rights to Peptide Therapeutic for Skin Disorders
  
• CompuGen, DiscoveRx to Develop Peptides Against GPCRs
  
• Unigene Regains Oral rPTH Osteoporosis Candidate from GSK
  
• Janssen, Molecular Partners Expand Agreement to Immunological Diseases
  
• BioLineRx to Develop Compugen Candidates Against Multiple Diseases
  
• ProtAffin Receives €2.1M Austrian Grant to Take IL-8 Decoy into Clinic
  
• Takeda Backs Out of Commercializing Affymax’ Anemia Drug in Japan
  
• Xenome Secures about $6.2M to Advance Peptide-Based Pain Med
  
• Warburg Pincus Invests Another $8.1M in Protox Therapeutics
  
• Apogenix Wins €2.3M to Develop Drug for Myelodysplastic Syndrome
  
• Apogenix Raises €7.5M to Progress Glioblastoma Drug Through Phase II
  
• Targovax Raises $2.2M to Progress Vaccine into Phase II Pancreatic Cancer Trials